Shah C - Search Results

1

Longitudinal Retinal Perfusion Status in Eyes with Diabetic Macular Edema Receiving Intravitreal Aflibercept or Laser in VISTA Study.

Wykoff CC, Shah C, Dhoot D, Coleman HR, Thompson D, Du W, Baker K, Vitti R, Berliner AJ, Metzig C, Saroj N. Wykoff CC, et al. Among authors: shah c. Ophthalmology. 2019 Aug;126(8):1171-1180. doi: 10.1016/j.ophtha.2019.03.040. Epub 2019 Apr 1. Ophthalmology. 2019. PMID: 30946887 Clinical Trial.

2

Retinal pigment epithelial tear after intravitreal bevacizumab injection.

Shah CP, Hsu J, Garg SJ, Fischer DH, Kaiser R. Shah CP, et al. Am J Ophthalmol. 2006 Dec;142(6):1070-2. doi: 10.1016/j.ajo.2006.07.037. Epub 2006 Sep 12. Am J Ophthalmol. 2006. PMID: 17157598

3

Treatment of acute retinal necrosis.

Tibbetts MD, Shah CP, Young LH, Duker JS, Maguire JI, Morley MG. Tibbetts MD, et al. Ophthalmology. 2010 Apr;117(4):818-24. doi: 10.1016/j.ophtha.2009.09.001. Epub 2010 Jan 15. Ophthalmology. 2010. PMID: 20079537

4

Outcomes and risk factors associated with endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor agents.

Shah CP, Garg SJ, Vander JF, Brown GC, Kaiser RS, Haller JA; Post-Injection Endophthalmitis (PIE) Study Team. Shah CP, et al. Ophthalmology. 2011 Oct;118(10):2028-34. doi: 10.1016/j.ophtha.2011.02.034. Epub 2011 Jun 25. Ophthalmology. 2011. PMID: 21705087

5

Electroretinographic effects of omega-3 Fatty Acid supplementation on dry age-related macular degeneration.

Gerstenblith AT, Baskin DE, Shah CP, Wolfe JD, Fineman MS, Kaiser RS, Ho AC. Gerstenblith AT, et al. Among authors: shah cp. JAMA Ophthalmol. 2013 Mar;131(3):365-9. doi: 10.1001/jamaophthalmol.2013.642. JAMA Ophthalmol. 2013. PMID: 23494041

6

Aflibercept for exudative AMD with persistent fluid on ranibizumab and/or bevacizumab.

Cho H, Shah CP, Weber M, Heier JS. Cho H, et al. Br J Ophthalmol. 2013 Aug;97(8):1032-5. doi: 10.1136/bjophthalmol-2013-303344. Epub 2013 Jun 13. Br J Ophthalmol. 2013. PMID: 23766432

7

Expanded criteria for pneumatic retinopexy and potential cost savings.

Goldman DR, Shah CP, Heier JS. Goldman DR, et al. Ophthalmology. 2014 Jan;121(1):318-326. doi: 10.1016/j.ophtha.2013.06.037. Epub 2013 Aug 14. Ophthalmology. 2014. PMID: 23953099

8

Initial utilization of aflibercept in exudative age-related macular degeneration.

Cho H, Weber ML, Shah CP, Heier JS. Cho H, et al. Eur J Ophthalmol. 2014 Jul-Aug;24(4):576-81. doi: 10.5301/ejo.5000421. Epub 2014 Mar 17. Eur J Ophthalmol. 2014. PMID: 24706352

9

Noninfectious inflammation after intravitreal injection of aflibercept: clinical characteristics and visual outcomes.

Goldberg RA, Shah CP, Wiegand TW, Heier JS. Goldberg RA, et al. Am J Ophthalmol. 2014 Oct;158(4):733-737.e1. doi: 10.1016/j.ajo.2014.06.019. Epub 2014 Jun 28. Am J Ophthalmol. 2014. PMID: 24983791

10

Incidence and clinical features of post-injection endophthalmitis according to diagnosis.

Rayess N, Rahimy E, Shah CP, Wolfe JD, Chen E, DeCroos FC, Storey P, Garg SJ, Hsu J. Rayess N, et al. Among authors: shah cp. Br J Ophthalmol. 2016 Aug;100(8):1058-61. doi: 10.1136/bjophthalmol-2015-307707. Epub 2015 Nov 19. Br J Ophthalmol. 2016. PMID: 26584579

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,341 results

Search Page

Filters